drugset / Trial / NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or R/R diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.
Timeline
- Start
- 2020-04-29
- Primary completion
- 2024-08-28
- Completion
- 2024-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-10188 | Unknown | 20 mg | Oral |
| Subject | BGB-10188 | Unknown | 40 mg | Oral |
| Subject | BGB-10188 | Unknown | 60 mg | Oral |
| Subject | BGB-10188 | Unknown | 80 mg | Oral |
| Subject | BGB-10188 | Unknown | 120 mg | Oral |
| Subject | BGB-10188 | Unknown | 160 mg | Oral |
| Subject | BGB-10188 | Unknown | 240 mg | Oral |
| Subject | BGB-10188 | Unknown | 320 mg | Oral |
| Subject | BGB-10188 | Unknown | 360 mg | Oral |
| Subject | BGB-10188 | Unknown | 540 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |